紧随强制执行后，要约人全堡集团有限公司、罗名译先生及与彼等任何一方一致行动人士于2755.9万股 股份(相当于该公司于本公告日期全部已发行股本约68.90%)中拥有权益。因此，要约人须根据收购守则 规则26.1就所有已发行股份(要约人、罗名译先生及与彼等任何一方一致行动人士已拥有或同意将予收 购者除外)提出强制无条件全面现金要约。每股要约股份现金0.223港元，较于最后交易日在联交所所报 收市价每股0.485港元折让约54.02%。 裕丰昌控股(08631)公布，鉴于王新龙先生的个人财务压力，加上该公司不断恶化的财务状况及迫切的 营运资金需求，罗名译先生于2025年5月22日向王新龙先生授予贷款550万港元，并已于同日提取。该贷 款按每年15%的利率计息，且应于自提款日期起计五个历月(即2025年10月21日)届满时偿还。 要约在所有方面均为无条件，且不以接获最低数目股份的接纳或任何其他条件为条件。 该贷款提供予王新龙先生用于结清其个人债务以解除当时由其实益拥有股份的现有产权负担及为该公司 的营运资金需求提供资金。尤其是，根据贷款协议，贷款须按以下方式予以运用：(i)170万港元用于解 除当时为支持2024年 ...

据罗名译先生所深知、尽悉及确信，于授予贷款后，王新龙先生的财务状况及该公司的流动性进一步恶 化。该等情况构成贷款协议项下的重大不利变动，并引发违约事项。尤其是，根据贷款协议，违约事件 包括贷款人罗名译先生认为存在合理理由相信发生下列任何情况的情形：该公司的业务、财务状况或前 景出现重大不利变动，或王新龙先生或任何其他责任方履行其义务的能力已经或将会受到重大不利影 响。就罗名译先生所深知及确信，于强制执行股份押记日期，王新龙先生未能履行因2024年全面要约而 产生的重大个人义务，包括欠付申万宏源融资(香港)有限公司(香港裕丰昌的2024年全面要约财务顾问) 的尚未支付的专业费用。此外，该公司未能结清应向其专业服务提供商支付的款项，欠款逾90万港元。 该等专业服务提供商中的几家提供商自2025年8月初以来已就尚未支付的费用发出催缴函或法律通知。 该等情况证明其持续无力履行财务义务并触发贷款协议项下的违约事件。因此，于2025年8月6日，于违 约之后，罗名译先生强制执行其于股份押记协议下的权利，导致于同日向其转让所有押记股份。 紧随强制执行后，要约人全堡集团有限公司、罗名译先生及与彼等任何一方一致行动人士于2755 ...

Group 1 - The core point of the article is that Shenke Co., Ltd. announced a comprehensive tender offer from Shenzhen Huili Hongsheng Industrial Holdings for all shareholders at a price of 16.13 yuan per share, covering 86.5875 million shares, which represents 57.73% of the company's total equity [1] - The tender offer period is set from July 29, 2025, to August 27, 2025 [1] - As of August 27, 2025, the tender offer period will expire, and the company's stock will be suspended from trading starting August 28, with the resumption date pending the announcement of the tender offer results [1]

Group 1 - The core point of the news is the announcement of a family internal equity structure adjustment at Jichuan Pharmaceutical, which triggers a mandatory general offer for the company's shares by Cao Fei, the son of the actual controller, Cao Longxiang [1][2] - On June 11, Cao Longxiang transferred 10.10% of his shares in Jichuan Holdings to Cao Fei for 10.1 million yuan, resulting in Cao Fei holding 60% of Jichuan Holdings and indirectly controlling 5.17 billion shares of Jichuan Pharmaceutical, which is 56.07% of the total share capital [1] - The general offer price is set at 26.93 yuan per share, requiring a maximum total funding of 9.448 billion yuan, with the offer period lasting from June 18, 2025, to July 17, 2025 [2] Group 2 - Jichuan Pharmaceutical's major shareholder structure remains unchanged after the transfer, with Jichuan Holdings holding 4.17 billion shares, accounting for 45.22% of the total share capital, and the combined holdings of the controlling shareholder and concerted parties reaching 61.15% [1] - The company reported a revenue of 1.525 billion yuan in the first quarter of 2025, a year-on-year decrease of 36.51%, and a net profit attributable to shareholders of 440 million yuan, down 47.91% year-on-year [3] - The decline in revenue is attributed to two main factors: a high base in the first quarter of 2024 and the impact of centralized procurement on the main product, Rabeprazole Sodium Enteric-coated Capsules [3]